Stoke Therapeutics Inc. (STOK) — closed signal from January 27, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 27, 2026 — +13% at the close.
Predicted vs. what happened
What happened
Reached its target in 27 days.
The thesis — published January 27, 2026
Stoke is a risky stock that could bounce in the next 0-3 months after recent big price swings. The company gave new timing for a late-stage drug study and will present at a major healthcare conference, which can bring new attention. Because trading is thin, buy small and wait for clear price improvement before increasing size; sudden big moves are possible.
Primary drivers
- New clinical timing can change what investors expect
- Conference presentation can attract fresh investor interest
- Price could rebound after recent large swings
- Biotech events can give uneven but big upside
How it played out
STOK: target reached in 27 days
Lyra published STOK at $29.85 on January 27, 2026, with 20% expected growth over a short-term window ending April 27, 2026. The thesis pointed to new timing for a late-stage drug study, a healthcare conference presentation, a possible rebound after large price swings, and uneven but large upside around biotech events.
Inside the window, STOK reached the $35.81 target in 27 days. It later peaked at $40.22 on March 10, 2026, for a 34.8% gain. By the window close, it ended at $33.71. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.